Presentations in this session:

10:20 WeOa0201    Abstract Powerpoint Investigating cellular antiretroviral resistance: preliminary results of the “ICARE” study Lafeuillade A.1, Hittinger G.1, Poggi C.2, Benech H.3, Cupo A.4 1CHITS, Toulon, France, 2General Hospital, Toulon, France, 3CEA, Gif sur Yvette, France, 4CNRS, Sofia Antipolis, France

10:30 WeOa0202    Abstract Powerpoint Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients Pozniak A.L.1, Gallant J.E.2, DeJesus E.3, Campo R.4, Arribas J.R.5, Gazzard B.1, Lu B.6, McColl D.6, Enejosa J.6, Cheng A.K.6 1Chelsea and Westminster Hospital, London, United Kingdom, 2Johns Hopkins University School of Medicine, Baltimore, United States of America, 3Orlando Immunology Center, Orlando, United States of America, 4University of Miami, Miami, United States of America, 5University Hospital La Paz, Madrid, Spain, 6Gilead Sciences, Foster City, United States of America

10:40 WeOa0203    Abstract The level of persistent viremia does not increase after simplification of maintenance antiretroviral therapy to lopinavir/ritonavir alone. McKinnon J.E.1, Arribas J.R.2, Pulido F.3, Delgado R.3, Mellors J.W.1 1University of Pittsburgh, Pittsburgh, United States of America, 2Hospital La Paz, Madrid, Spain, 3Hospital Doce de Octubre, Madrid, Spain

10:50 WeOa0204    Abstract Powerpoint Viral suppression in CSF and genital tract in ritonavir-boosted "atazanavir only" maintenance therapy (ATARITMO-Study) Vernazza P.1, Daneel S.1, Schiffer V.2, Decosterd L.3, Hirschel B.2, and the Swiss HIV Cohort S.1 1Cantonal Hospital, St. Gallen, Switzerland, 2University Hospital Geneva, Geneva, Switzerland, 3CHUV, Lausanne, Switzerland

11:00 WeOa0205    Abstract Powerpoint Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients. Valdez H.1, McCallister S.1, Kohlbrenner V.1, Mayers D.1 1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States of America

11:10 WeOa0206    Abstract Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation Awni W.1, Chiu Y.-L.1, Zhu T.1, Braun N.1, Klein C.1, Heuser R.1, Breitenbach J.1, Morris J.1, Doan T.1, Brun S.1, Hanna G.1 1Abbott Laboratories, Abbott Park, IL, United States of America